+2,682.0%
SMCI vs GSK
+136.2%
+2,545.7%
-84.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.0% | -1.3% | +2.3% | +1.7% |
| 7D | -19.9% | -3.1% | -16.8% | -18.6% |
| 30D | -24.1% | -0.9% | -23.2% | -24.2% |
| 3M | -34.9% | -4.2% | -30.7% | -34.3% |
| 6M | -21.0% | -1.6% | -19.4% | -22.7% |
| YTD | -16.7% | +2.6% | -19.3% | -20.3% |
| 1Y | -30.2% | +6.2% | -36.4% | -34.6% |
| 3Y | -15.6% | +55.0% | -70.5% | -39.3% |
| 5Y | +468.6% | +42.8% | +425.8% | +312.5% |
| 10Y | +839.1% | +102.1% | +737.0% | +424.4% |
| All | +2,682.0% | +136.2% | +2,545.7% | +1,144.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling